scispace - formally typeset
J

Jenette Creaney

Researcher at University of Western Australia

Publications -  123
Citations -  8106

Jenette Creaney is an academic researcher from University of Western Australia. The author has contributed to research in topics: Mesothelioma & Mesothelin. The author has an hindex of 40, co-authored 113 publications receiving 6246 citations. Previous affiliations of Jenette Creaney include Sir Charles Gairdner Hospital & University of Stirling.

Papers
More filters
Journal ArticleDOI

Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.

Katherine A Hoadley, +738 more
- 05 Apr 2018 - 
TL;DR: Molecular similarities among histologically or anatomically related cancer types provide a basis for focused pan-cancer analyses, such as pan-gastrointestinal, Pan-gynecological, pan-kidney, and pan-squamous cancers, and those related by stemness features, which may inform strategies for future therapeutic development.
Journal ArticleDOI

Genomic and Functional Approaches to Understanding Cancer Aneuploidy

Alison M. Taylor, +732 more
- 09 Apr 2018 - 
TL;DR: The genomic and phenotypic correlates of cancer aneuploidy are defined and genome engineering is applied to delete 3p in lung cells, causing decreased proliferation rescued in part by chromosome 3 duplication.
Journal ArticleDOI

Mesothelin-family proteins and diagnosis of mesothelioma.

TL;DR: Determined serum concentrations of soluble mesothelin-related proteins (SMR) in serum could be a useful marker for diagnosis of mesothelioma and to monitor disease progression and might also prove helpful for screening asbestos-exposed individuals for early evidence of mesosarcoma.
Journal ArticleDOI

Integrative Molecular Characterization of Malignant Pleural Mesothelioma

Julija Hmeljak, +58 more
- 15 Oct 2018 - 
TL;DR: A comprehensive integrated genomic study of 74 MPMs provided a deeper understanding of histology-independent determinants of aggressive behavior, defined a novel genomic subtype with TP53 and SETDB1 mutations and extensive loss of heterozygosity, and discovered strong expression of the immune-checkpoint gene VISTA in epithelioid MPM.